Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2

By C. Ferrario, Jewell A. Jessup, M. Chappell, D. Averill, K. Brosnihan, E. Tallant, D. Diz, Patricia E. Gallagher. Circulation, 2005

1,475 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/a4674e1bef2c31660bd36decfbe38c018090fd90

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Rhian M. Touyz
2. M. Grant
3. J. Zhong
4. A. Marian
5. Judith Hochman
6. G. Oudit

In Molecular Biology

1. M. Grant
2. J. Zhong
3. I. McInnes
4. G. Oudit
5. Rhian M. Touyz

Citations in the corpus

• SARS-CoV-2 and viral sepsis: observations and hypotheses (2020, background): “Some researchers suggested that ACE inhibitors might benefit these patients by reducing pulmonary inflammation, 29 although others argued that ACE inhibitors might enhance viral entry by regulating ACE2 levels. 30 However, there has been little clinical evidence on the risk of treating COVID-19 pati”
• Cardiovascular disease and COVID-19 (2020, background): “Since SARS-CoV-2 binds to ACE2 to gain entry into human cells, there is a potentially increased risk of developing COVID-19 or developing more severe disease in patients who are already on background treatment with ACEi/ARB. However, to date, no experimental or clinical data have emerged to support ”
• COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options (2020, background): “34 Experimental studies demonstrated that inhibition of the RAAS with ACE inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) may result in a compensatory increase in tissue levels of ACE2, 35 leading to suggestions that these drugs may be detrimental in patients exposed to SARS-CoV-2.”
• The pivotal link between ACE2 deficiency and SARS-CoV-2 infection (2020, neutral): “The possibility that ACE inhibitors and angiotensin II receptor blockers (ARBs) may be discontinued even temporarily, because these drugs appear to increase the expression of ACE2 receptors, the site of viral entry into the human organism, [72] [73] [74] [75] is actively debated.”
• Renin‐angiotensin system revisited (2008, background): “This leads to organ-wise regulated increase of local production of Ang 1-7, as demonstrated in rats [48] [49] [50] .”
• Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System (2020, background): “179, 180 These findings could be attributed to tissue-specific regulation of ACE2, as higher ACE2 protein levels were reported in the heart, but ACE2 activity was higher in the kidneys of Sprague-Dawley rats, adding to the complexity of the tissue RAS. 186 In type 1 diabetic Akita angiotensinogen-tr”
• Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19 (2020, background): “[2] [3] [4] [5] [6] [7] Some have suggested that calciumchannel blockers, which do not act on the RAAS, may be the preferred antihypertensive agents during the Covid-19 pandemic.”